Intellia Therapeutics, Inc.
NTLA- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001652130
In the last 90 days, Intellia Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 329 institutions reported holding it in 13F filings for Q2 2026, worth $2.43B in total; ARK Invest is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Intellia Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 4 filings
- 3 insiders, $506.6K in total
- Insiders trading
- 3
- Net value
- −$506.6K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Intellia Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Leonard John M | President and CEO | 1,147,064 | Aug 24, 2026 | 4 |
| Dulac Edward J III | EVP, Chief Financial Officer | 148,175 | Jul 24, 2026 | 4 |
| Dube Michael P | VP, Chief Accounting Officer | 66,886 | Jul 6, 2026 | 4 |
| Cohen Fred E | Director | 216,653 | Jun 10, 2026 | 2 |
| Verwiel Frank | Director | 35,148 | Jun 10, 2026 | 1 |
| Goff Brian | Director | 32,609 | Jun 10, 2026 | 1 |
| Chase William J | Director | 143,893 | Jun 10, 2026 | 1 |
| Goodman Jesse | Director | 33,559 | Jun 10, 2026 | 1 |
| Keresty Georgia | Director | 41,083 | Jun 10, 2026 | 1 |
| Bhanji Muna | Director | 36,403 | Jun 10, 2026 | 1 |
| Basta James | EVP, General Counsel | 156,794 | Mar 3, 2026 | 2 |
| Lebwohl David | EVP, Chief Medical Officer | 131,192 | Mar 3, 2026 | 2 |
| Clark Eliana | EVP, Chief Technical Officer | 93,864 | Mar 3, 2026 | 2 |
| Schultes Birgit C | EVP, Chief Scientific Officer | 137,733 | Mar 3, 2026 | 3 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 77,388 | Jan 7, 2025 | 0 |
| Hicks Derek | EVP, Chief Business Officer | 59,878 | Jan 7, 2025 | 0 |
| Goddard Glenn | EVP, Chief Financial Officer | 69,213 | Mar 5, 2024 | 0 |
| Crowley John F | Director | 11,716 | Jun 16, 2023 | 0 |
| Formela Jean Francois | Director | 7,291 | Jun 16, 2022 | 0 |
| Dorsa Caroline | Director | 12,701 | Jun 16, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 7, 2025 (view filing) | Jan 3 | 4 days | Basta JamesEVP, General Counsel | SSale | −7.07K | $12.18 | −$86.2K | −8.7%74.5K after | |
| Jan 7, 2025 (view filing) | Jan 3 | 4 days | Dube Michael PVP, Chief Accounting Officer | SSale | −1.37K | $12.18 | −$16.7K | −2.9%45.6K after | |
| Jan 31, 2025 (view filing) | Jan 29 | 2 days | Bhanji MunaDirector | SSale | −265 | $9.97 | −$2.64K | −1.3%19.5K after | 10b5-1 |
| Mar 4, 2025 (view filing) | Mar 4 | Same day | Basta JamesEVP, General Counsel | SSale | −2.57K | $8.99 | −$23.1K | −2.2%111.9K after | |
| Mar 4, 2025 (view filing) | Mar 4 | Same day | Clark ElianaEVP, Chief Technical Officer | SSale | −679 | $8.99 | −$6.10K | −0.7%95.4K after | |
| May 1, 2025 (view filing) | Apr 29 | 2 days | Bhanji MunaDirector | SSale | −265 | $8.50 | −$2.25K | −1.4%19.2K after | 10b5-1 |
| Jul 2, 2025 (view filing) | Jun 30-Jul 1 | 2 days | Goodman JesseDirector | SSale | −3.09K | $9.40 | −$29.1K | −11.3%24.4K after | 2 lots10b5-1 |
| Jul 3, 2025 (view filing) | Jul 2 | 1 day | Dube Michael PVP, Chief Accounting Officer | SSale | −2.50K | $9.95 | −$24.9K | −4.2%57.1K after | |
| Jul 3, 2025 (view filing) | Jul 1 | 2 days | Clark ElianaEVP, Chief Technical Officer | SSale | −1.02K | $9.82 | −$10.0K | −1.1%95.4K after | |
| Jul 25, 2025 (view filing) | Jul 23 | 2 days | Dulac Edward J IIIEVP, Chief Financial Officer | SSale | −7.46K | $14.02 | −$104.6K | −6.6%106.1K after | |
| Aug 22, 2025 (view filing) | Aug 20 | 2 days | Chase William JDirector | PPurchase | +100.0K | $10.03 | +$1.00M | +288.2%134.7K after | |
| Oct 3, 2025 (view filing) | Oct 1 | 2 days | Dube Michael PVP, Chief Accounting Officer | SSale | −1.87K | $17.38 | −$32.5K | −3.3%55.3K after | |
| Oct 3, 2025 (view filing) | Oct 1 | 2 days | Schultes Birgit CEVP, Chief Scientific Officer | SSale | −31 | $17.38 | −$538.78 | 0.0%105.2K after | |
| Dec 12, 2025 (view filing) | Dec 11 | 1 day | Leonard John MPresident and CEO | SSale | −88.1K | $9.49 | −$836.4K | −7.8%1.04M after | 3 lots10b5-1 |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Dube Michael PVP, Chief Accounting Officer | SSale | −2.99K | $9.21 | −$27.5K | −5.4%52.3K after | |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Dulac Edward J IIIEVP, Chief Financial Officer | SSale | −6.38K | $9.21 | −$58.8K | −6.0%99.7K after | |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Clark ElianaEVP, Chief Technical Officer | SSale | −9.52K | $9.21 | −$87.6K | −9.8%87.1K after | |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Lebwohl DavidEVP, Chief Medical Officer | SSale | −11.9K | $9.21 | −$109.6K | −8.9%121.2K after | |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Cohen Fred EDirector | PPurchase | +150.0K | $9.35 | +$1.40M | +261.1%207.5K after | |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Basta JamesEVP, General Counsel | SSale | −10.4K | $9.21 | −$95.8K | −9.3%101.5K after | |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Schultes Birgit CEVP, Chief Scientific Officer | SSale | −8.51K | $9.21 | −$78.4K | −7.9%98.5K after | |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Leonard John MPresident and CEO | SSale | −34.1K | $9.21 | −$314.5K | −3.3%1.01M after | |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Clark ElianaEVP, Chief Technical Officer | SSale | −607 | $13.78 | −$8.36K | −0.6%93.9K after | |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Basta JamesEVP, General Counsel | SSale | −1.21K | $13.78 | −$16.7K | −0.8%156.8K after | |
| Jul 6, 2026 (view filing)5:01 PM ET | Jul 2 | 4 days | Dulac Edward J IIIEVP, Chief Financial Officer | SSale | −4.68K | $18.00 | −$84.2K | −2.9%156.3K after | 10b5-1 |
| Jul 6, 2026 (view filing)5:02 PM ET | Jul 1 | 5 days | Dube Michael PVP, Chief Accounting Officer | SSale | −2.64K | $16.78 | −$44.3K | −3.8%66.9K after | |
| Jul 24, 2026 (view filing)5:26 PM ET | Jul 22 | 2 days | Dulac Edward J IIIEVP, Chief Financial Officer | SSale | −8.11K | $11.25 | −$91.2K | −5.2%148.2K after | |
| Aug 24, 2026 (view filing)4:05 PM ET | Aug 20-21 | 4 days | Leonard John MPresident and CEO | SSale | −22.7K | $12.65 | −$286.8K | −1.9%1.15M after | 2 lots10b5-1 |